ClinicalTrials.gg
RecruitingNCT07397455COVHIC003Updated Jul 17, 2026

Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants

A Phase 1 interventional study of SARS-CoV-2 Omicron EG.5.1 challenge agent 10^5 TCID50 and SARS-CoV-2 Omicron EG.5.1 challenge agent 10^6 TCID50 in SARS-CoV-2 (COVID-19), sponsored by Imperial College London. Recruiting at 5 sites in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Imperial College London · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in COVID-19 by Imperial College London — 2 open to participants now, 4 under way, none of them phase 3. COVID-19 · Imperial College London.

Started
2026
the only one that year
Phase 1
2 of 19
1 open now
Registered
19th of 19
by date

Among the 19 studies in COVID-19 by Imperial College London, this one is the only one that started in 2026, is one of 2 in phase 1, and was the 19th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 19 studies in COVID-19 by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in COVID-19 by Imperial College London, or all of them as a file.
02

Study summary

COVHIC003 is a human infection challenge study in which healthy adults aged 18-50 previously vaccinated with an approved COVID-19 vaccine will be administered a SARS-CoV-2 Omicron EG.5.1 variant given by drops in the nose. The aim is to achieve breakthrough upper-respiratory infection in a proportion of volunteers with mild or no illness, providing information on the course of Omicron infection and the immune response in vaccinated people. This study will establish an optimised challenge dose and model that can then be used to evaluate new vaccines and treatments in follow-on trials. Participants will stay in a quarantine unit for approximately 10-12 days, depending on infection status, and will be closely monitored with regular swabs, blood tests and symptom assessments throughout their stay. They will be followed up by the study team for 6 months after being discharged. This study is sponsored by Imperial College London and forms part of the MUSICC project which is led by Imperial College London and co-funded by the European Union's Horizon Europe Programme and the Coalition for Epidemic Preparedness Innovations (CEPI). Quarantine will take place at specialist facilities in Oxford or at the Royal Free Hospital in London.

03

Conditions studied

  • SARS-CoV-2 (COVID-19)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The study form has been signed and dated by the participant and the Investigator
  • Adults age between 18 and 50 years inclusive (at the time of enrolment)
  • Evidence of having had at least one COVID-19 vaccine, with the last vaccination at least 3 months before enrolment
  • Positive serology for SARS-CoV-2 at (pre)screening
  • Sero-suitable as defined by having serum and/or nasal antibody titres less than a pre-defined cut-off of a defined assay(s) which will be specified in a separate SOP and based on accumulating antibody data
  • People of (POCBP) must be willing and able to use as described in the study protocol from 2 weeks before the scheduled date of viral challenge until the end discharge from quarantine.

Negative urine pregnancy tests will be required at screening and on day 0 prior to inoculation. On admission to the quarantine unit a negative serum beta human chorionic gonadotropin (β-hCG) is required

  • Male participants who are willing to use one of the contraception methods described in the study protocol, from the time of the date of viral challenge until the end of quarantine
  • Agree to abstain from sexual activity or use effective contraception from the start of treatment with Paxlovid until 7 days after completing treatment with Paxlovid should they receive it
  • In good health with no history of medical conditions (as described in Exclusion criteria) that would interfere with participant safety, as defined by medical history, physical examination and routine laboratory tests, , and Chest X-Ray and determined by the Investigator at an admission evaluation
  • Participants will have a documented medical history either prior to entering the study and/or following medical history review with the study physician at screening
  • Willing to be registered with The Over-Volunteering Protection Service (TOPS)
  • Willing and able to commit to participation in the study.

Exclusion criteria

Exclusion Criteria:

  • History or evidence of any or currently active cardiovascular, (including thromboembolic events), respiratory, dermatological, gastrointestinal, endocrine, haematological, hepatic, immunological, rheumatological, metabolic, urological, renal, neurological, psychiatric illness
  • Any significant abnormality altering the anatomy or function of the nose or nasopharynx in a substantial way (including loss of or alterations in smell or taste), a clinically significant history of epistaxis (large nosebleeds) within the last 3 months, nasal or sinus surgery within 6 months of inoculation
  • Clinically-active, symptomatic rhinitis (including hay fever) or history of severe rhinitis, or seasonal allergic rhinitis likely to be active at the time of inclusion into the study and/or requiring regular nasal on an at least weekly basis, within 30 days of admission to quarantine
  • History of anaphylaxis and/or a history of severe allergic reaction or significant intolerance to any food or drug, as assessed by the Investigator
  • Significant history or presence of drug or alcohol misuse (exceeding >28 units a week)
  • Current use of any drugs taken through the nasal or inhaled route including recreational drugs
  • Psychiatric illness including participants with a history of depression and/or anxiety with associated severe psychiatric comorbidities, for example psychosis.
  • Current active smokers, equivalent to >5 cigarettes per week, including use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g., gum, patch) or electronic cigarettes. • Participants who have smoked ≥5 pack years at any time [5 pack years is equivalent to one pack of 20 cigarettes a day for 5 years]) or the equivalent amount of nicotine if using alternative forms. • Ex-smokers who have smoked \<5 pack years at any time must not of have regularly smoked in the last 3 months equivalent to >5 cigarettes per week.
  • Family history of 1st degree relative aged 50 years or less with sudden cardiac or unexplained death
  • Personal or Family History of unexpectedly severe COVID-19, adverse response to any other viral disease e.g. Guillain-Barré, or a family history (described as a 1st degree relative) with clotting disorders
  • A total body weight of ≤ 45kg and a (BMI) ≤18 kg/m2 and ≥28 kg/m2. The upper limit of BMI may be increased to ≤ 30kg/m2 at the Investigator's discretion, in the case of physically fit muscular individual
  • Venous access deemed inadequate for the phlebotomy demands of the study.
  • Any clinically significant abnormal finding on screening biochemistry, haematology and microbiology blood tests or urinalysis i.e. grade 1 lab abnormalities or above apart from minor deviations which are clinically acceptable and approved by the Investigator
  • A (FEV1) and a forced vital capacity (FVC) \<80% of predicted value calculated using ATS/ERS guidance. Spirometry will be performed only if the mMRC dyspnoea score ≥1 or if clinically indicated
  • Twelve-lead recording with clinically relevant abnormalities as judged by the Investigator
  • History of, or currently active symptoms suggestive of upper or lower respiratory tract infection (including reduced sense of taste and smell, raised body temperature and/or persistent cough) within 4 weeks prior to viral challenge
  • Presence of cold-like symptoms and/or fever (defined as participant presenting with a temperature reading of >37.9ºC) on Day -2, Day -1 and/or pre-challenge on Day 0.
  • Evidence of any respiratory pathogens (on Respiratory PCR from upper respiratory tract sample) prior to challenge virus inoculation on admission to the quarantine unit
  • Evidence of a within 60 days prior to the planned date of viral challenge, a non-live vaccine within 30 days prior to the planned date of viral challenge or intention to receive any vaccination(s) before the day 28 follow-up visit. (NB. No travel restrictions applied after the Day 28 Follow-up visit).
  • Receipt of blood or blood products, or loss (including blood donations) of 550 mL or more of blood during the 3 months prior to the planned date of viral challenge or planned during the 3 months after the final visit.
  • Medications

    1. Use of any medication or product (prescription or over-the-counter), for symptoms of hay fever, nasal congestion or respiratory tract infections or dermatitis/eczema including the use of regular nasal or medium-high potency dermal corticosteroids, antibiotics and First Defence™ (or generic equivalents) within 7 days prior to the planned date of viral challenge apart from those described in Table 7, Permitted Medication or agreed by the Investigator.
    2. Receipt of any drug within 3 months prior to the planned date of viral challenge.
    3. Receipt of three or more investigational drugs within the previous 12 months prior to the planned date of viral challenge.
    4. Receipt of systemic (intravenous and/or oral) glucocorticoids or antiviral drugs known to have activity against respiratory viruses within 6 months prior to the planned date of viral challenge (excluding Pre-Exposure Prophylaxis (PrEP)).
    5. Over the counter medications (e.g., paracetamol or ibuprofen) where the dose taken over the preceding 7 days prior to the planned date of viral challenge had exceeded the maximum permissible 24-hour dose (e.g., >4g per day of paracetamol over the preceding week).
    6. Chronically used medications, including any medication known to be a moderate/potent inducer or inhibitor of cytochrome P450 enzymes, within 21 days prior to the planned date of viral challenge, except for those agreed by the Investigator.
    7. Participants who have received any systemic chemotherapy agent, immunoglobulins, or other cytotoxic or drugs at any time.
    8. Concurrent use of medications strongly for use with Paxlovid unless confirmed alternative rescue therapy will be available to the site at the time of enrolment
  • Prior participation in another human viral challenge study in the preceding 6 months taken from the date of viral challenge in the previous study to the date of expected viral challenge in this study. The participant must also have completed the follow up visit requirements of the previous viral challenge study
  • Any invasive nasal sampling procedure in the month before date of expected viral challenge in this study (excluding study tolerance test or routine tests for COVID-19)
  • Participant is mentally or legally incapacitated in the opinion of the Investigator
  • POCBP who:

    1. Are breastfeeding within 6 months of study commencement, or
    2. Had been pregnant within 6 months prior to the study, or
    3. Had a positive pregnancy test at any point during screening or prior to inoculation with challenge virus
  • Those in close domestic contact (i.e. sharing a household with, caring for, or daily face to face contact) with children under 2 years, the elderly (>65 years), immunosuppressed persons, or those with chronic respiratory disease
  • Anyone who works on the study (e.g. a delegated study nurse) or in close proximity to the study at the sponsor organisation, participating trial sites or any contract research organisations involved in this study.
  • Anyone who is first degree related to, or resides with, anyone who is a delegated member of the research team at a study site
  • Any other reason that the Investigator considered made the participant unsuitable to participate
  • Participants with no knowledge of their family history
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Group 1a: SARS-CoV-2 Omicron EG.5.1

    Starting dose 10\^5 TCID50, vaccinated, pre-selection for low serum antibodies, n = up to 12

    Biological: SARS-CoV-2 Omicron EG.5.1 challenge agent 10^5 TCID50

  • Experimental
    Group 1b: SARS-CoV-2 Omicron EG.5.1

    Dose escalate: 10\^6 TCID50, vaccinated, pre-selection for low serum antibodies, n = up to 12

    Biological: SARS-CoV-2 Omicron EG.5.1 challenge agent 10^6 TCID50

  • Experimental
    Group 1c: SARS-CoV-2 Omicron EG.5.1

    Dose de-escalate: 10\^4 TCID50, vaccinated, pre-selection for low serum antibodies, n = up to 12

    Biological: SARS-CoV-2 Omicron EG.5.1 challenge agent 10^4 TCID50

  • Experimental
    Group 2: SARS-CoV-2 Omicron EG.5.1

    10\^6 TCID50 with multiple doses and/or lower sero-screening threshold

    Biological: SARS-CoV-2 Omicron EG.5.1 challenge agent 10^6 TCID50

Interventions

  • BiologicalSARS-CoV-2 Omicron EG.5.1 challenge agent 10^5 TCID50

    10\^5 TCID50 This is a SARS-CoV-2 Omicron EG.5.1 challenge agent which has not been given in controlled human infection studies previously.

  • BiologicalSARS-CoV-2 Omicron EG.5.1 challenge agent 10^6 TCID50

    10\^6 TCID50 This is a SARS-CoV-2 Omicron EG.5.1 challenge agent which has not been given in controlled human infection studies previously

  • BiologicalSARS-CoV-2 Omicron EG.5.1 challenge agent 10^4 TCID50

    10\^4 TCID50 This is a SARS-CoV-2 Omicron EG.5.1 challenge agent which has not been given in controlled human infection studies previously

06

What researchers measure

Primary outcomes

  1. To assess the safety and human clinical response to intranasal challenge of SARS-CoV-2 EG.5.1 variant in healthy participants who are immunologically experienced against SARS-CoV-2.

    To evaluate the safety of Omicron variant SARS-CoV-2 challenge in healthy participants, by assessing: • Occurrence of AEs within 28 days post-viral challenge (Day 0 to Day 28)

    Time frame: 28 Days

  2. To assess the safety and human clinical response to intranasal challenge of SARS-CoV-2 EG.5.1 variant in healthy participants who are immunologically experienced against SARS-CoV-2.

    To evaluate the safety of Omicron variant SARS-CoV-2 challenge in healthy participants, by assessing: • • Occurrence of SAEs related to the viral challenge (Day 0 to Day 180)

    Time frame: 180 Days

  3. Selection of the SARS-CoV-2 Omicron EG.5.1 dose(s) required to induce laboratory confirmed upper respiratory tract infection in 50-70% of immunologically experienced, healthy participants following intranasal challenge

    Laboratory confirmed infection is defined as: two quantifiable (≥LLOQ) RT-PCR measurements from mid turbinate or throat samples, reported on 2 or more consecutive timepoints, starting from Day 2 (inclusive) post-inoculation and up to discharge from quarantine (Day 8 for uninfected participants or Day 10 for infected participants)

    Time frame: 10 Days

07

Study locations

3 of 5 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.

Of 151 non-industry phase 1 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's planned 17 months is above that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 9, 2026
StartActual
Jul 10, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07397455
Collaborators
Imperial College Healthcare NHS Trust, University College, London, University of Oxford, Royal Free Hospital NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust, Oxford University Hospitals NHS Trust
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
Jul 10, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 17, 2026

Study contacts

Polly Fox-Sheehan, BSc, MSc
Contact
polly.fox@imperial.ac.uk
+4420 3313 1282
Christopher Chiu, BMBCh FRCP FRCPath PhD
principal investigator · Imperial College London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion